© 2022 MJH Life Sciences™ and Modern Retina. All rights reserved.
Ophthalmology Times Staff Reports
Articles
Bausch Health: Spin-off of eye health business
August 06, 2020
Article
This action will result in 2 separate companies
DME therapy with plasma kallikrein inhibitor showing promise
May 03, 2016
Article
Results from a phase I study of KVD001 (KalVista Pharmaceuticals) for the treatment of central involved diabetic macular edema (CIDME) show that this plasma kallikrein inhibitor was well-tolerated, not associated with any ophthalmic or systemic safety signals, and led to fairly long-lasting improvements in visual acuity (VA) and central retinal thickness (CRT) after a single intravitreous injection.